Table 2 Clinical features of Klebsiella species bloodstream infection
Factor | K. pneumoniae (n = 113) | K. oxytoca (n = 35) | p-value |
|---|---|---|---|
Median age (IQR) | 72.4 (62.4–81.3) | 64.3 (52.4–76.1) | 0.07 |
Male | 62 (55%) | 24 (69%) | 0.2 |
Acquisition | 0.012 | ||
HO | 23 (20%) | 1 (3%) | |
HA | 61 (54%) | 27 (77%) | |
CA | 29 (26%) | 7 (20%) | |
Focus | 0.68 | ||
Primary/no focus | 12 (11%) | 4 (11%) | |
Bone and joint | 2 (2%) | 1 (3%) | |
Soft tissue | 3 (3%) | 1 (3%) | |
Respiratory | 14 (12%) | 1 (3%) | |
Cardiovascular | 2 (2%) | 1 (3%) | |
Intra-Abdominal | 46 (4%) | 15 (43%) | |
Genitourinary | 35 (31%) | 12 (34%) | |
Antibiotic susceptible | |||
Ampicillin | 2/111 (3%) | 1/35 (3%) | 0.6 |
Cefazolin | 95/102 (93%) | 9/35 (26%) | < 0.0001 |
Ceftriaxone | 72/72 (100%) | 29/30 (97%) | 0.1 |
Ciprofloxacin | 107/108 (99%) | 34/35 (97%) | 0.4 |
Gentamicin | 111/111 (100%) | 35/35 (100%) | |
Co-trimoxazole | 100/104 (96%) | 32/34 (94%) | 0.6 |
Median CCI (IQR) | 2 (1–4) | 1.5 (1–3) | 0.46 |